Neuromodulator Comparison
Botox
vs Daxxify
OnabotulinumtoxinA vs DaxibotulinumtoxinA-lanm
Written by the Vera Beauty Editorial Team · Last updated March 2026
Both are FDA-approved botulinum toxin type A neuromodulators that relax facial muscles to reduce dynamic wrinkles. The key difference is duration and formulation: Botox lasts 3–4 months and uses albumin as a stabilizer, while Daxxify uses a proprietary peptide (RTP004) and lasts approximately 6 months. Daxxify costs more per session but typically requires fewer annual treatments.
|
Botox |
Daxxify |
| Neuromodulator injection |
Neuromodulator injection |
| OnabotulinumtoxinA |
DaxibotulinumtoxinA-lanm |
| Human serum albumin |
Synthetic peptide (RTP004) |
| 2002 (glabellar lines) |
2022 (glabellar lines) |
| 3–7 days; full effect ~2 weeks |
3–7 days; full effect ~2 weeks |
| 3–4 months (typical) |
~6 months (median in SAKURA trials) |
| ~$300–$600 (glabellar, 20 u) |
~$600–$900 (glabellar, 40 u) |
| Mild — fine-gauge needle, brief pinch |
Mild — similar to Botox |
| None; avoid strenuous activity 24 h |
None; avoid strenuous activity 24 h |
| Glabellar, forehead, crow's feet |
Glabellar lines only (as of 2026) |
| First-timers, multi-area treatment, budget-conscious |
Established patients wanting fewer visits |
Botox remains the go-to for most patients — broader FDA approvals, a shorter duration that works in your favor if you're still finding your ideal result, and a lower per-session cost. Daxxify earns its place once you know what works for you and want to cut your annual visits from 3–4 sessions down to 2. Both deliver comparable results; the decision really comes down to where you are in your treatment journey.
How does Botox work?
Botox (onabotulinumtoxinA) is a purified form of botulinum toxin type A that blocks neuromuscular signaling at the injection site. After the toxin is taken up by the nerve terminal via receptor-mediated endocytosis, it cleaves SNAP-25 — a synaptosomal-associated protein required for acetylcholine vesicle fusion[9]. Without SNAP-25 intact, the nerve terminal cannot release acetylcholine, and the target muscle cannot contract.
The result is a temporary, localized reduction in muscle movement in the treated area. Dynamic wrinkles — those caused by repeated muscle contractions like frowning, squinting, or raising the brows — soften as the muscle remains at rest. The effect is fully reversible: as nerve terminals regenerate and new SNAP-25 is synthesized, muscle function gradually returns.
Botox was first approved for cosmetic use in 2002 for moderate to severe glabellar lines, with subsequent approvals for forehead lines and crow's feet. Clinically, it has been studied in glabellar lines in multiple large randomized controlled trials, with consistent findings of meaningful improvement in wrinkle severity at doses of 20 units[7].
▸
In the phase 3 clinical studies supporting FDA approval, 80% of Botox-treated patients achieved none or mild glabellar line severity at Day 30, compared to 3% in the placebo group[8].
How does Daxxify work?
Daxxify (daxibotulinumtoxinA-lanm) shares the same fundamental mechanism as Botox — it is a botulinum toxin type A that cleaves SNAP-25 at the neuromuscular junction, preventing acetylcholine release and temporarily relaxing the target muscle. The key differentiation is in its formulation. Where Botox uses human serum albumin to keep the toxin stable in solution, Daxxify uses a proprietary synthetic stabilizing peptide called RTP004.
RTP004 is believed to interact with the toxin's heavy chain, enhancing its binding affinity at the nerve terminal and slowing the onset of nerve regeneration. This mechanism is what Revance, the manufacturer, attributes to Daxxify's extended duration. Because the peptide is synthetic and not derived from human blood products, Daxxify is also human albumin-free — a distinction some providers and patients consider relevant[3].
Daxxify received FDA approval in September 2022 for moderate to severe glabellar lines in adults. Its approval was supported by the SAKURA 1 and SAKURA 2 phase 3 trials, which demonstrated both comparable efficacy to existing neuromodulators and a significantly extended duration of effect[1].
▸
In the pooled SAKURA 1 and SAKURA 2 data, 74% of Daxxify-treated patients achieved a 2-grade improvement in glabellar line severity at maximum contraction on day 30, versus 0% in the placebo group[2].
How long do Botox results last compared to Daxxify?
Duration is the most clinically meaningful difference between the two products. Botox results in the glabellar area typically last 3–4 months in most patients, with some variation based on muscle mass, metabolic rate, and dose. Research on onabotulinumtoxinA's pharmacodynamic response confirms that most patients begin to see return of muscle movement between 10 and 16 weeks post-treatment, with full return within 3–6 months[6].
Daxxify demonstrates meaningfully longer duration. In the pooled SAKURA trial data, the median response duration was 24 weeks (6 months), with 47.7% of patients still classified as responders at the 6-month mark[2]. A subset of patients maintained response for up to 9 months. This extended duration is not observed with any other currently FDA-approved neuromodulator.
▸
Pooled SAKURA data shows Daxxify's median duration of 24 weeks (6 months) — roughly 1.5–2× longer than the typical 10–16 week duration of Botox in the same glabellar indication[2].
It is worth noting that individual variation is substantial for both products. Patients with very expressive facial muscles, high metabolic rates, or heavy physical activity levels may find their results on either product wear off sooner than average. Duration also tends to improve with consistent long-term treatment, as the treated muscles gradually weaken with disuse.
How much does Botox cost compared to Daxxify?
Botox for glabellar lines is typically priced per unit, at roughly $12–$20 per unit depending on provider and market. A standard glabellar treatment uses 20 units of Botox, bringing the per-session cost to approximately $300–$600. Treating additional areas — forehead lines (~10–15 units) or crow's feet (~10–12 units per side) — adds to the total. Most patients treating multiple areas spend $600–$1,200 per Botox session.
Daxxify is most commonly priced per session rather than per unit, reflecting its fixed 40-unit standard dose for glabella. Sessions typically run $600–$900. The per-session cost is higher, but because Daxxify lasts roughly twice as long as Botox, the annual cost comparison narrows considerably. A patient who would otherwise have 3–4 Botox sessions per year may require only 2 Daxxify sessions — potentially at similar or slightly higher annual cost depending on local pricing.
Annual cost estimate: At 3 Botox sessions at $450 each = $1,350/year vs. 2 Daxxify sessions at $750 each = $1,500/year — a difference of approximately $150 annually for many patients. These figures are illustrative estimates — actual pricing varies by market, provider, and unit dosage used per session.
Daxxify's cost advantage is most pronounced for patients who treat only the glabellar area. For patients who treat multiple facial areas — where Botox has broader FDA approvals and more established off-label protocols — Botox is often the more economical choice overall.
What are the side effects of Botox vs Daxxify?
Both products share a similar safety profile at cosmetic doses, reflecting their shared mechanism of action. The most common side effects for both are injection-site reactions: mild bruising, redness, swelling, or tenderness that resolves within a few days. Headache is reported in a small percentage of patients following either treatment, usually resolving within 24–48 hours.
The most clinically significant adverse event for any neuromodulator injection in the upper face is eyelid ptosis (drooping) or brow ptosis, which occurs when toxin diffuses beyond the intended injection site. This is technique-dependent and more related to injector skill and anatomy than to the specific product. Ptosis is temporary and resolves as the product metabolizes, but it can persist for several weeks.
▸
In the large open-label phase 3 safety study of DaxibotulinumtoxinA (n=2,691 subjects), injection-site bruising occurred in 3.0% of cycles and headache in 4.4%; serious adverse events were rare and not attributed to the study drug[4].
Daxxify's extended duration, while a clinical benefit for most patients, also means that any unwanted effect — including excessive muscle relaxation or ptosis — takes longer to resolve than with Botox. This is one reason many injectors recommend that first-time neuromodulator patients begin with Botox, where any dissatisfaction resolves within a few months rather than six or more. Neither product is appropriate during pregnancy or breastfeeding.
Which is right for you: Botox or Daxxify?
The decision between Botox and Daxxify is primarily driven by three factors: treatment history, treatment area, and how much you value duration versus flexibility. Neither product is objectively superior — the right choice depends on your individual situation.
| If you… |
Consider |
Reason |
| Are new to neuromodulators |
Botox |
Shorter duration means any unwanted result resolves faster. More established safety record. |
| Want to treat forehead + crow's feet |
Botox |
Botox holds FDA approvals for all three upper-face areas; Daxxify is approved only for glabella. |
| Treat only frown lines and want fewer visits |
Daxxify |
2 sessions per year instead of 3–4. Median 6-month duration from SAKURA trials. |
| Have an established result you love |
Daxxify |
If you already know your dose and preferred look, the longer duration is a convenience benefit. |
| Are budget-conscious per session |
Botox |
Lower upfront cost per session; spreads spend more evenly across the year. |
| Prefer albumin-free formulations |
Daxxify |
Daxxify's RTP004 peptide stabilizer contains no human blood-derived proteins. |
For most patients already happy with their Botox results, switching to Daxxify is a reasonable option when they are ready to reduce treatment frequency. The efficacy profiles are comparable — both products achieve meaningful improvement in glabellar line severity — so the choice is largely about duration preference and cost tolerance rather than one product being more effective than the other[3].
What questions should you ask your provider before choosing Botox or Daxxify?
Bring these to your consultation to make a more confident decision:
- How long do your patients typically see results with Botox vs Daxxify in this treatment area? Real-world duration varies by injection technique, muscle mass, and patient metabolism.
- What unit dosage do you use for each, and how does that affect the total session cost? Daxxify units are not equivalent to Botox units — ask for the per-session all-in price, not the per-unit rate.
- Have you treated patients who've switched between neuromodulators? A provider with experience on both can speak to how their results compare in practice.
- Do I have any contraindications that would make one option safer for me? Certain neuromuscular conditions, medications, and anatomical factors influence which neuromodulator is appropriate.
- What's your touch-up policy if my results fade faster than expected? Understanding this upfront helps you plan around important events and budget for maintenance.